Home › Research › Disparities
The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials
Rebekah M. Ahmed, Olivier Piguet, Catherine Jane Mummery, Sharon Linda Naismith, Muireann Irish. The Lancet Regional Health - Western Pacific, 2025-02-01
Topic: Risk, prevention and care in population studies
In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come with significant burdens on the healthcare system that may limit access to treatment and care for patients. Often patients in remote and rural regions and those in low income regions are disadvantaged. Many clinical trials for dementia patients are biased to recruiting a homogenous group of patients that does not represent cultural and linguistic diversity, meaning the generalisability of trials is limited. This viewpoint discusses the barriers to access to early treatments and clinical trials for patients with dementia and offers a potential framework to address these including provision of infrastructure, regulatory change and patient education.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ahmed, R. M., Piguet, O., Mummery, C. J., Naismith, S. L., & Irish, M. (2025). The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials. The Lancet Regional Health - Western Pacific. https://doi.org/10.1016/j.lanwpc.2025.101492
Vancouver
Ahmed RM, Piguet O, Mummery CJ, Naismith SL, Irish M. The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials. The Lancet Regional Health - Western Pacific. 2025. doi:10.1016/j.lanwpc.2025.101492. PMID: 39995763.
BibTeX
@article{ahmed2025-39995763,
author = {Ahmed, Rebekah M. and Piguet, Olivier and Mummery, Catherine Jane and Naismith, Sharon Linda and Irish, Muireann},
title = {{The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials}},
journal = {The Lancet Regional Health - Western Pacific},
year = {2025},
doi = {10.1016/j.lanwpc.2025.101492},
pmid = {39995763},
url = {https://doi.org/10.1016/j.lanwpc.2025.101492}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come with significant burdens on the healthcare system that may limit access to treatment and care for patients.
Why it matters
This viewpoint discusses barriers to equitable access to dementia treatments and clinical trials, noting that patients in remote, rural, and low-income regions are disadvantaged and that trials often recruit homogeneous groups. It offers a potential framework involving infrastructure, regulatory change, and patient education, but reports no treatment, cure, or prevention results.
New to this subject? Start with our plain-English guide: Disparities →
Study details
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Lancet Regional Health - Western Pacific) |
| Journal's citation record | 0 / 4 | The Lancet Regional Health - Western Pacific: journal h-index 66 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Muireann Irish: h-index 54 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39995763) |
| Free to read | 2 / 2 | Free to read |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.lanwpc.2025.101492
- PubMed: 39995763
- Original source →
- Free full text: The Lancet Regional Health - Western Pacific →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Disparities
Also tagged “prevalence”
1,223 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,223 tagged studies.